On August 25, 2023, the executive meeting of The State Council was held to review and adopt the Action Plan for High-quality Development of the Pharmaceutical Industry 

(2023-2025) and the Action Plan for high-quality Development of the Medical equipment Industry (2023-2025).

The two "action plans" put forward a series of specific measures, including focusing on improving the resilience and modernization level of the pharmaceutical industry and 

medical equipment industry, and speeding up the shortcomings of China's high-end medical equipment; Strengthen the support of the whole chain, encourage and guide 

the development and growth of leading pharmaceutical enterprises, and improve industrial concentration and market competitiveness; Safeguarding the safety of TCM 

development; Pay attention to the promotion and application of domestic medical equipment, and promote the iterative upgrading of domestic medical equipment; Strengthen 

the training of cross-disciplinary talents in medical industry.

In 2023, the high-quality development of China's pharmaceutical industry will reach a new level. Up to now, there are more than 10,000 pharmaceutical industry enterprises 

above designated size in China, and the number of new drugs in research ranks second in the world. New breakthroughs have been made in the innovation and development 

of the medical equipment industry, such as China's first fully autonomous and controllable ECMO complete machine system approved for listing. The launch of the two "action 

plans" will further accelerate the pace of high-quality development of China's pharmaceutical industry and medical equipment industry.